Oncology Brothers: Practice-Changing Cancer Discussions

Discussion on Evolving CLL Treatment Strategies with Dr. Nitin Jain

In this informative podcast episode, the Oncology Brothers delve into the world of hematologic malignancies, focusing specifically on Chronic Lymphocytic Leukemia (CLL). Dr. Nitin Jain from MD Anderson Cancer Center joins the discussion, sharing insights on the latest treatment options and guidelines for CLL.
The episode covers essential topics such as determining when a patient with CLL needs treatment, the minimal workup required for scans and biopsies, and the decision-making process between time-limited venetoclax and long-term BTK inhibitors. Dr. Jain also discusses the use of second-generation BTK inhibitors like Acalabrutinib and Zanabrutinib, as well as the recent approvals of Partibrutinib and CAR-T  for third-line treatment.
Tune in to gain a deeper understanding of CLL treatment strategies, managing side effects, and the evolving landscape of hematologic malignancies. Don't miss out on this insightful conversation that will benefit both healthcare professionals and patients navigating CLL treatment options.
Stay informed and stay tuned for upcoming episodes on multiple myeloma and myelofibrosis with the Oncology Brothers. Subscribe now to stay updated on the latest in oncology care.

FRESCO2 Study: FDA Approval of Fruquintinib for Refractory Colorectal Cancer

Join us for yet another episode of The Oncology Brothers podcast, where we delve into the FRESCO2 study in metastatic colorectal cancer. In this episode, we are joined by Dr. Arvind Dasari from MD Anderson, the lead author of the study, to discuss the approval of fruquintinib and its impact on refractory colorectal cancer patients.
Discover how fruquintinib has significantly improved progression-free and overall survival, providing a new treatment option for patients who have exhausted other therapies. Dr. Dasari shares insights on the study design, results, and the practical implications of incorporating fruquintinib into clinical practice.
Tune in to learn about the key findings, side effects, dosing strategies, and real-world experiences with fruquintinib in managing refractory colorectal cancer. Take advantage of this informative episode that sheds light on the evolving landscape of colon cancer treatments. Subscribe to The Oncology Brothers podcast for more insightful discussions on cancer care. #Oncology #ColorectalCancer #FRESCO2Study
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Standard of Care Treatment for Upper GI Cancer: A Discussion with Dr. Sam Clempner

Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Sam Klempner, a medical oncologist specializing in upper GI malignancies. Together, they delve into the current treatment strategies for esophageal, GE junction, and gastric adenocarcinoma.
The discussion covers a range of topics, including the evolving paradigms in neoadjuvant and adjuvant therapies, the importance of biomarker testing such as MSI and PD-L1, and the potential impact of new targets like Claudin 18.2 in upper GI cancers. Dr. Klempner also shares insights on the management of metastatic disease, including the role of targeted therapies like TDXD and Zolbetuximab.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the current landscape of upper GI malignancies. Stay informed and join the Oncology Brothers as they navigate the complexities of treating these challenging cancers. Don't miss out on this informative discussion!
Tune in to the Oncology Brothers podcast for more expert insights and discussions on oncology topics. Remember to like, share, and subscribe for more content on the latest developments in cancer care. Thank you for listening!

Standard of Care Treatment for Colon Cancer: A Discussion with Dr. Aparna Parikh

In this episode of Oncology Brothers, join hosts Drs. Rahul and Rohit as they dive into the management of colon cancer with special guest Dr. Aparna Parikh, a medical oncologist from Mass General Hospital. Dr. Parikh shares insights on the treatment algorithm for colon cancer, including the use of circulating tumor DNA and the latest advancements in treatment options. From localized disease to metastatic space, the discussion covers key aspects of managing colon cancer. Tune in to learn about the evolving landscape of colon cancer treatment and the importance of personalized patient-centered care. Don't miss out on this informative episode with the Oncology Brothers and Dr. Aparna Parikh!

Unpacking the Treatment Algorithm of Hepatocellular Carcinoma with Dr. Tanios S. Bekaii-saab

Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, in this engaging podcast episode as they delve into the treatment landscape for hepatocellular carcinoma (HCC) with Dr. Tanios S. Bekaii-saab from Mayo Clinic. The discussion covers the treatment options for different stages of HCC, including liver transplant, local therapy, and systemic treatments. Dr. Tanios S. Bekaii-saab provides insights on utilizing Atezolizumab with Bevacizumab, dual checkpoint inhibitors, and TKIs in advanced or metastatic HCC. Clinical pearls on managing side effects and patient selection criteria are also discussed. Don't miss this comprehensive overview of HCC treatment strategies in both community and academic settings. Stay informed and educated on the latest developments in oncology with the Oncology Brothers podcast series. Subscribe now for more insightful discussions on various cancer types and treatment approaches. #Oncology #HepatocellularCarcinoma #CancerTreatment #PodcastEpisode

Breakthrough in Bladder Cancer: FDA approval - Enfortumab Vedotin + Pelbrolizumab with Dr. Tom Powles

Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, as they dive deep into the groundbreaking EV302 study with special guest Dr. Thomas Powles. In this episode, they discuss the approval of Enfortumab and Pembrolizumab as a combination therapy for advanced bladder cancer, based on the remarkable results of the study. Dr. Powles shares insights on the study design, findings, and the transformative impact of the treatment on patients' lives. Discover how this new standard of care in bladder cancer has significantly improved overall survival benefits, with a median survival of 31.5 months compared to 16.1 months with chemotherapy. The discussion also delves into managing the side effects of the treatment and the potential use of ctDNA in monitoring disease progression. Don't miss this informative episode that sheds light on the evolving landscape of bladder cancer treatment and the hope it brings to patients. Stay tuned for a quick recap and insights from the Oncology Brothers.

Bladder Cancer Treatment Algorithm Discussion with Drs. Karine Tawagi and Sia Daneshmand

Bladder Cancer Treatment Options: A Comprehensive Discussion | Oncology Brothers Podcast
 
Join the Oncology Brothers, Rahul Gosain and Rohit Gosain, in this insightful podcast episode where they are joined by Dr. Karine Tawagi, a medical oncologist, and Dr. Sia Daneshmand, a urologist, to discuss the current standard of care and treatment options for bladder cancer. In this episode, the experts delve into the treatment approaches for non-muscle invasive bladder cancer, including the use of BCG, pembrolizumab, and other emerging therapies. They also cover the management of muscle invasive bladder cancer, highlighting the role of neoadjuvant chemotherapy, cystectomy, and immunotherapy. The conversation extends to metastatic bladder cancer, focusing on the groundbreaking EV Pembro treatment and the evolving landscape of treatment options post-progression. The experts provide valuable insights into managing toxicities associated with different therapies and offer clinical pearls for healthcare providers. Don't miss this informative discussion on bladder cancer treatment options, featuring expert insights and practical recommendations for healthcare professionals. Tune in to the Oncology Brothers Podcast now! Listen to the full episode here. Stay informed and updated on the latest advancements in oncology with the Oncology Brothers podcast series. Subscribe now for more engaging discussions and expert insights.
#Bladder #Cancer #Treatment #Algorithm
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Exploring the Latest in Renal Cell Cancer Therapies with Dr. Monty Pal using an Algorithm

In this episode joined by Dr. Monty Pal from City of Hope to discuss the latest advancements in the treatment of renal cell cancer. The conversation covers topics such as adjuvant pembrolizumab, personalized medicine, second-line treatment options, and the role of TKIs and immune checkpoint inhibitors. Dr. Pal shares insights on clinical pearls, treatment algorithms, and ongoing clinical trials in the field. Tune in to stay informed about the current standard of care practices in renal cell cancer treatment.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

How to treat Prostate Cancer in 2024 with Dr. Rana McKay

In discussion with Dr. Rana McKay, Associate Professor of Medicine from UC San Diego Health, we covered the treatment algorithm for Prostate cancer, starting from localized disease and then focusing on CSPC and CRPC.
 
#Prostate #Cancer #Cancer #2024 #oncology #oncbrothers
 
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 Study

In this discussion with Dr. Hope Rugo, we covered her study Capitello-291, which led to the approval of Capivasertib in hormone receptor-positive breast cancer with AKT1, PTEN, and PIK3CA mutations, which are seen in 40-50% of the cases. We touched base on sequencing of this therapy, and important clinical pearls around the side effect management associated with this drug.